Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Activations

CCTG PA.7: A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma

The primary objective is to determine the effect on overall survival of the addition of durvalumab + tremelimumab to standard 1st-line chemotherapy with gemcitabine/nab-paclitaxel in patients with metastatic pancreatic cancer.

Secondary objectives are to:
  • Determine the effect on progression free survival (PFS) of the addition of durvalumab + tremelimumab to standard 1st line chemotherapy with gemcitabine/nab-paclitaxel in patients with metastatic pancreatic cancer;
  • To assess the toxicity and safety of durvalumab + tremelimumab in combination with gemcitabine/nab-paclitaxel in patients with metastatic pancreatic cancer; and,
  • To determine the effect on objective response rate (ORR) of the addition of durvalumab + tremelimumab to standard 1st line chemotherapy with gemcitabine/nab-paclitaxel in patients with metastatic pancreatic cancer.
Any interested centres should contact Barbara Graham, Study Coordinator, at bgraham@ctg.queensu.ca.
_____________________________________

IND.232: A Phase II Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Metastatic Castration Resistant Prostate Cancer

The primary objective is to determine the objective response rate (RECIST 1.1 and irRECIST) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with durvalumab alone or in combination with tremelimumab.

Secondary objectives are to:
  • Determine the prostate-specific antigen (PSA) response rate as time to PSA progression;
  • Evaluate time to objective disease progression; and,
  • Evaluate toxicity.
Interested qualified centres should contact Caitlin Burns, Study Coordinator, at cburns@ctg.queensu.ca.